(60 Tests)

CK-MB is found predominantly in cardiac muscle cells, accounting for approximately 10-40% of myocardial CK. Concentration levels of CK-MB in blood aids in the diagnosis and monitoring of myocardial injury.

PATHFAST determines the quantity of CK-MB from both whole blood and plasma samples, providing results within minutes, and facilitating critical care decisions for patients with acute myocardial infarction, deep vein thrombosis, pulmonary embolism and congestive heart failure.

FDA Cleared for Moderate Complexity Labs - Not CLIAwaived.


Assay range:  1 - 250 ng/mL

Total imprecision at 2.69 ng/mL, near the 97.5% reference interval of 3.01 ng/mL:  8.1%

Correlation between lithium heparin plasma and whole blood:  R = 0.997

Correlation between lithium heparin plasma and EDTA-2K plasma:  R = 0.995

Correlation between lithium heparin plasma and EDTA-2K whole blood:  R = 0.990


*Data above listed on the product indication for use (IFU)

© 2020 Cliawaived, Inc. All Rights Reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.